<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04841265</url>
  </required_header>
  <id_info>
    <org_study_id>CIRB 2021/2055</org_study_id>
    <nct_id>NCT04841265</nct_id>
  </id_info>
  <brief_title>The Effect of Vitamin D Supplementation in Overweight and Obese Pregnant Women</brief_title>
  <official_title>The Effect of Vitamin D Supplementation in Overweight and Obese Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KK Women's and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KK Women's and Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To understand the role of vitamin D supplementation on pregnancy outcomes and metabolic&#xD;
      status in overweight and obese pregnant women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effects of vitamin D supplementation on pregnancy outcomes and metabolic status of&#xD;
      overweight and obese pregnant women remain uncertain. In particular, the dosage of vitamin D&#xD;
      supplementation has not been defined in this high risk group of women. This study aims to&#xD;
      examine whether oral supplement of vitamin D3 (cholecalciferol) in total dosage of 800&#xD;
      IU(prenatal multivitamin containing 400 IU vitamin D3 + 400 IU vitamin D3 alone) given to&#xD;
      overweight and obese pregnant women since early pregnancy until delivery can improve maternal&#xD;
      and neonatal outcomes, compared with those given prenatal multivitamin containing 400 IU&#xD;
      vitamin D3 supplementation, a commonly given antenatal supplement in Singapore. The&#xD;
      investigators' hypothesis is that higher dose vitamin D supplementation would lead to better&#xD;
      outcomes in overweight and obese pregnant women. The investigators will conduct a two-arm,&#xD;
      parallel non-blinded randomized controlled trial. Women with body mass index ≥25kg/m2 will be&#xD;
      randomly assigned into groups with a 1:1 randomization ratio, receiving either 800 or 400 IU&#xD;
      vitamin D3 supplementation. The study will be conducted at the antenatal clinics, KK Women's&#xD;
      and Children's Hospital, Singapore. Measurements of serum 25-hydroxyvitamin D (25OHD), lipid&#xD;
      profile and lifestyles information will be taken for all women at baseline (≤16 weeks&#xD;
      gestation) and after three months of intervention (26-30 weeks gestation). All women will&#xD;
      continue with the vitamin D3 supplementation until delivery. Primary outcomes include levels&#xD;
      of maternal serum 25OHDconcentration and lipid profile at 26-30 gestation weeks as compared&#xD;
      with the controls, adjusting for baseline measurements. Secondary outcomes include&#xD;
      preeclampsia, gestational hypertension, gestational diabetes, glycaemic levels, caesarean&#xD;
      section, gestational weight gain, preterm birth, low birth weight and&#xD;
      small-for-gestational-age. This study will fill up the gap of knowledge regarding the role of&#xD;
      vitamin D supplementation on pregnancy outcomes and metabolic status in overweight and obese&#xD;
      pregnant women.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2021</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in maternal serum 25OHD concentration</measure>
    <time_frame>Baseline, 26-30 gestational weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maternal total cholesterol level</measure>
    <time_frame>Baseline, 26-30 gestational weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maternal HDL-cholesterol level</measure>
    <time_frame>Baseline, 26-30 gestational weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maternal LDL-cholesterol level</measure>
    <time_frame>Baseline, 26-30 gestational weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in maternal triglyceride level</measure>
    <time_frame>Baseline, 26-30 gestational weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of preeclampsia</measure>
    <time_frame>up to delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gestational hypertension</measure>
    <time_frame>Through pregnancy until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of gestational diabetes</measure>
    <time_frame>Through pregnancy until delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting glucose level</measure>
    <time_frame>24-28 gestational weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-hour post-load glucose level</measure>
    <time_frame>24-28 gestational weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hour post-load glucose level</measure>
    <time_frame>24-28 gestational weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of caesarean section</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of preterm birth (&lt;37 weeks)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of low birth weight (&lt;2500g)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth weight (g)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal birth length (cm)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal head circumference (cm)</measure>
    <time_frame>At delivery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of admission to special care (including intensive care) during neonatal period</measure>
    <time_frame>Within 28 days after delivery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Overweight and Obesity</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Vitamin D3 (intervention) arm will receive a total of 800 IU vitamin D3 supplementation per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control arm will receive 400 IU vitamin D3 per day from routine antenatal multivitamin supplementation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>The intervention arm will receive 400 IU vitamin D3 from routine antenatal multivitamin supplement tablet + 400 IU vitamin D3 daily until delivery.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Gestation ≤16weeks (16 weeks + 6 days) upon intervention&#xD;
&#xD;
          2. Pre-pregnancy BMI ≥25 kg/m2&#xD;
&#xD;
          3. Aged 21-45 years&#xD;
&#xD;
          4. Willing and able to provide written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Having current or past hypo/hyperparathyroidism, hypercalciuria, hypercalcemia or&#xD;
             osteomalacia&#xD;
&#xD;
          2. History of renal disease (including kidney stones and etc.), liver dysfunction,&#xD;
             tuberculosis or sarcoidosis&#xD;
&#xD;
          3. Pre-existing diabetes mellitus or chronic hypertension&#xD;
&#xD;
          4. Taking lipid-lowering medicine&#xD;
&#xD;
          5. Gestational diabetes (as confirmed by oral glucose tolerance test) or gestational&#xD;
             hypertensive disorder&#xD;
&#xD;
          6. Multiple pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Overweight and obese pregnant women</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Loy See Ling, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KK Women's and Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benjarat Oh</last_name>
    <phone>83684641</phone>
    <email>benjarat.oh@kkh.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Si Xuan Rachael Loo</last_name>
    <phone>82990112</phone>
    <email>rachael.loo.s.x@kkh.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KK Women's and Children's Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Ling Loy, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>June 26, 2021</last_update_submitted>
  <last_update_submitted_qc>June 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>KK Women's and Children's Hospital</investigator_affiliation>
    <investigator_full_name>Loy See Ling</investigator_full_name>
    <investigator_title>Senior Research Fellow</investigator_title>
  </responsible_party>
  <keyword>Vitamin D supplementation</keyword>
  <keyword>Lipid profile</keyword>
  <keyword>Vitamin D status</keyword>
  <keyword>Birth outcomes</keyword>
  <keyword>Pregnancy complications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

